Publication | Closed Access

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

OncologyPathologyBronchial NeoplasmDacomitinib Versus GefitinibFirst-line TreatmentCancer TreatmentMedicineRadiation OncologyLung CancerMolecular OncologyCancer GrowthArcher 1050